MiNK Therapeutics (INKT) Insider Trading & Ownership $0.70 +0.02 (+2.92%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MiNK Therapeutics (NASDAQ:INKT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage19.73%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)$667,993.79Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$95,000.00 Get INKT Insider Trade Alerts Want to know when executives and insiders are buying or selling MiNK Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address INKT Insider Buying and Selling by Quarter Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. MiNK Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/16/2023Agenus IncMajor ShareholderBuy429$1.10$471.90 10/12/2023Agenus IncMajor ShareholderBuy3,173$1.10$3,490.30 10/4/2023Agenus IncMajor ShareholderBuy15,001$1.09$16,351.09 8/28/2023Agenus IncMajor ShareholderBuy12,808$1.45$18,571.60 8/24/2023Agenus IncMajor ShareholderBuy170,244$1.54$262,175.76 5/10/2023Agenus IncMajor ShareholderBuy22,065$1.51$33,318.15 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 5/5/2023Agenus IncMajor ShareholderBuy100,200$0.95$95,190.00 5/5/2023Garo H ArmenDirectorSell100,000$0.95$95,000.00 5/3/2023Agenus IncMajor ShareholderBuy128,689$1.08$138,984.12 5/2/2023Garo H ArmenDirectorBuy100,000$0.95$95,000.00 7/18/2022Ulf WiinbergDirectorBuy3,339$1.33$4,440.87 (Data available from 1/1/2013 forward) INKT Insider Trading Activity - Frequently Asked Questions Who is on MiNK Therapeutics's Insider Roster? The list of insiders at MiNK Therapeutics includes Agenus Inc, Garo H Armen, and Ulf Wiinberg. Learn more on insiders at INKT. What percentage of MiNK Therapeutics stock is owned by insiders? 19.73% of MiNK Therapeutics stock is owned by insiders. Learn more on INKT's insider holdings. Which MiNK Therapeutics insiders have been buying company stock? The following insiders have purchased INKT shares in the last 24 months: Agenus Inc ($568,552.92), and Garo H Armen ($95,000.00). How much insider buying is happening at MiNK Therapeutics? Insiders have purchased a total of 552,609 INKT shares in the last 24 months for a total of $663,552.92 bought. Which MiNK Therapeutics insiders have been selling company stock? The following insider sold INKT shares in the last 24 months: Garo H Armen ($95,000.00). How much insider selling is happening at MiNK Therapeutics? Insiders have sold a total of 100,000 MiNK Therapeutics shares in the last 24 months for a total of $95,000.00 sold. MiNK Therapeutics Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Executive Chairman Dr. Jennifer S. Buell Ph.D. (Age 48)President, CEO & Director Compensation: $916.75kDr. Marcus Antonius van Dijk Ph.D. (Age 62)Chief Scientific Officer Compensation: $458.28kMs. Christine M. Klaskin (Age 58)Treasurer Compensation: $29.62kJoy Zhou Ph.D.Vice President & Head of CMC More Insider Trading Tools from MarketBeat Related Companies Elevation Oncology Insider Buying Precision BioSciences Insider Buying Atara Biotherapeutics Insider Buying Celularity Insider Buying Adicet Bio Insider Buying Cabaletta Bio Insider Buying Vaxart Insider Buying Rani Therapeutics Insider Buying Journey Medical Insider Buying Century Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:INKT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INKT Stock Alerts